Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02210806 · ClinicalTrials.gov registry record · Phase 2
Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation
A Phase 2 study of Asthma, sponsored by Amphastar Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 4
- Study locations
NCT02210806 is a Phase 2 study of Asthma that has completed, run by Amphastar Pharmaceuticals. The registered enrollment target is 22 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02210806, a Phase 2 study of Asthma, has completed, sponsored by Amphastar Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study evaluates the efficacy, dose-ranging and safety profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 110 to 220 mcg per dose in comparison to a DPI Placebo Control and an Albuterol metered dose inhaler (MDI) Active Control.
Conditions Studied
Interventions
- DRUG A006 DPI
- OTHER Placebo DPI
- DRUG Proventil® MDI
Study Locations (4)
Texas
- Amphastar Site 0030 - New Braunfels
- Amphastar Site 0032 - San Antonio
California
- Amphastar Site 0001 - San Jose
Oregon
- Amphastar Site 0025 - Medford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-07 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02210806
The ClinicalTrials.gov registry entry for NCT02210806 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The listed sponsor is Amphastar Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which A006 DPI is the first listed.
NCT02210806 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Texas, California, Oregon.
Frequently Asked Questions
What is clinical trial NCT02210806 about?
NCT02210806 is a clinical study titled "Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation". This study evaluates the efficacy, dose-ranging and safety profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 110 to 220 mcg per dose in comparison to a DPI Placebo Control and an Albuterol metered dose inhaler (MDI) Active Control.
What is the current status of trial NCT02210806?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2014-07. Estimated completion is 2014-10.
What conditions does trial NCT02210806 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02210806?
The interventions under investigation include: A006 DPI (DRUG), Placebo DPI (OTHER), Proventil® MDI (DRUG).
Who is sponsoring clinical trial NCT02210806?
This trial is sponsored by Amphastar Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02210806 being conducted?
This trial has 4 study locations across California, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.